Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data
New York, January 6, 2026, 21:28 EST — Market closed Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology. The developments matter now because investors are looking for durable growth drivers heading into quarterly results later this month, when management is expected to frame demand trends and the pipeline into 2026. Late-stage filings and mid-stage readouts can move the outlook for a drugmaker even when the stock barely budges on the day, especially for a large-cap name where incremental product wins tend to show up in guidance